CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01361113
NCT01361113Phase 2Completed
CompareCT.gov

Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center·interventional·Posted May 26, 2011·Updated Apr 25, 2018

In Brief

A Phase 2 clinical trial evaluating Pazopanib for Renal Cell Carcinoma. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 26, 2011
Enrollment StartJun 1, 2011
Primary CompletionJan 7, 2015
Study CompletionFeb 15, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.1 years ago

Interventions

Pazopanibdrug

800 mg orally once daily for 8 weeks, prior to nephrectomy